FDA Scientists vs. RFK Jr.: The Evidence Battle That Could Decide Peptide Access

On June 30, 2026, FDA career scientists quietly posted a set of briefing documents online that threw cold water on one of the most anticipated regulatory decisions in the peptide world. Their conclusion: none of the seven peptides scheduled for review at the upcoming Pharmacy Compounding Advisory Committee meeting have sufficient evidence to support their use in humans.

This puts the FDA's own scientists on a direct collision course with Health and Human Services Secretary Robert F. Kennedy Jr., who has publicly championed expanded peptide access, called himself a "big fan" of the compounds, and personally used them on injuries with "really good effect."

The July 23-24 meeting at the FDA's White Oak Campus is now shaping up to be the most consequential regulatory showdown in peptide history. Here's what the briefing documents actually say, what the evidence looks like for each peptide, and what this means for anyone currently using or considering these compounds.

What the FDA Scientists Actually Found

The briefing documents, reviewed by NPR, the Washington Post, NBC News, and other outlets, paint a stark picture. For each of the seven peptides under review — BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and Emideltide — FDA scientists conducted systematic evidence reviews. Their findings were consistent: the data doesn't support the claims.

For three peptides — TB-500, KPV, and MOTS-c — the scientists could not find a single published human study. Not one. The entire body of evidence consists of animal models and in vitro experiments. That's a significant gap when you're talking about substances people are injecting into their bodies on a weekly basis.

For the remaining four — BPC-157, Semax, Epitalon, and Emideltide — the evidence was rated as "insufficient" for the specific medical conditions being claimed. That's not a technicality. It means the available studies were too small, too poorly designed, or too inconsistent to draw meaningful conclusions about whether these peptides actually work in humans.

Peptide-by-Peptide: The Evidence Gap

BPC-157 ("Wolverine Peptide") — This is the compound that generated the most debate. BPC-157 is marketed for injury recovery, ulcerative colitis, and gut healing. It's the most popular peptide in the gray market. But here's the uncomfortable truth: almost all the existing research comes from a single research group in Croatia, led by Dr. Predrag Sikiric. A 2026 narrative review published in PMC found only three pilot studies examining BPC-157 in humans — one for intraarticular knee pain, one for interstitial cystitis, and one IV safety/pharmacokinetics study. Dr. Flynn McGuire, a chief medical resident at the University of Utah who reviewed the research, told STAT News bluntly: "The amount of hype to evidence is just so skewed, it's crazy. BPC-157 should not be used by humans."

TB-500 (Thymosin Beta-4) — Marketed for wound healing and tissue repair. FDA scientists found zero published human studies. The compound has shown promise in animal models for cardiac repair and wound healing, but that's a long way from proving it works in people. There are no registered clinical trials on ClinicalTrials.gov for TB-500 as a standalone therapy.

KPV — A fragment of alpha-melanocyte-stimulating hormone, marketed for wound healing and inflammatory conditions. Again, no published human studies. The evidence base is entirely preclinical.

MOTS-c — A mitochondrial-derived peptide promoted for obesity and osteoporosis. No human studies. The research is interesting from a basic science perspective — MOTS-c appears to regulate metabolic homeostasis in mice — but the leap from mouse metabolism to human weight loss is enormous and unproven.

Semax — A synthetic analog of ACTH, used in Russia for cerebral ischemia and trigeminal neuralgia. Some Russian-language studies exist, but FDA scientists rated the evidence as insufficient for the claimed indications. The quality and reproducibility of the available data didn't meet the threshold for a compounding recommendation.

Epitalon — A tetrapeptide promoted for insomnia and anti-aging. Insufficient evidence. Most research comes from a single Ukrainian researcher, and the studies lack the rigor needed for regulatory decisions.

Emideltide (DSIP) — Delta sleep-inducing peptide, claimed for opioid withdrawal, chronic insomnia, and narcolepsy. Insufficient evidence for all claimed uses. The FDA noted that effective, approved treatments already exist for each of these conditions.

The Political Fault Line

This isn't just a scientific disagreement. It's a political one. Secretary Kennedy has made peptide access a personal priority. In a February podcast, he called the 2023 Biden administration ban on compounding these peptides "illegal" and argued that "these peptides do not pose any safety risks." He reclassified 12 peptides from Category 2 in April 2026, a first step toward allowing licensed compounding pharmacies to produce them.

Kennedy's argument has a practical dimension: the 2023 ban didn't eliminate peptide use. It pushed it underground. Today, peptides are sold online as "research chemicals" from gray market suppliers, many based in China, with no quality control, no medical oversight, and no recourse if something goes wrong. A regulated compounding pathway, proponents argue, would at least ensure pharmaceutical-grade products.

But the FDA scientists aren't buying the safety argument. Their briefing documents cite previous reviews that flagged contamination with heavy metals, microbial contamination, and mislabeling in compounded peptide products. They noted risks including priapism (prolonged, painful erections) and potential to aid tumor growth. And they pointed out that effective, approved treatments already exist for most of the conditions these peptides claim to treat.

C. Michael White, a pharmacy professor at the University of Connecticut, captured the contradiction succinctly: the same health leadership that demands "extremely large, multiyear randomized controlled trials" for vaccines is "perfectly happy to have a product that was only studied in rats and small animals being used in people."

The Panel Problem

Adding fuel to the controversy: the composition of the advisory panel itself. The FDA released the participant list for the July meeting on the same day the briefing documents were posted. According to multiple reports, the panel includes members who own or work at wellness centers that promote or sell peptides.

The seven peptides under review were originally nominated by a consulting firm and a pharmacy network representing the peptide and compounding industries — though both organizations have since withdrawn their nominations. The committee has only three voting members and six vacancies, which raises questions about whether a quorum of qualified, independent scientists will actually evaluate the evidence.

Dr. Anita Gupta, a former PCAC member, told NBC News that at previous meetings, "the FDA presented a lot of adverse event data that showed there was a risk of immunogenicity — immune reactions — and that raised some red flags for the committee." Whether the new panel will give that data the same weight remains to be seen.

The $2.2 Billion Question

There's a reason this fight is happening now, and it's not purely scientific. Wall Street analysts estimate that telehealth peptide prescribing could reach $2.2 billion annually if compounding restrictions are lifted. Hims & Hers, which acquired a U.S. peptide facility in 2025, could capture up to $440 million according to analyst estimates. The company has publicly supported the FDA's re-evaluation.

The compounding pharmacy industry stands to benefit enormously. So do the telehealth platforms that have built business models around peptide prescribing. The financial incentives are significant, which is exactly why the conflicts of interest on the advisory panel matter so much.

What This Means for Peptide Users

If you're currently using peptides or considering them, here's the honest picture:

The evidence base is thin. For most of the peptides under review, we're talking about animal studies, case reports, and small pilot trials — not the kind of large, randomized, controlled trials that would normally be required for a medical intervention. That doesn't mean these peptides don't work. It means we don't know yet.

The gray market is real and risky. People are already buying these peptides from unregulated sources. The quality is inconsistent at best. A regulated compounding pathway would improve product quality, but it wouldn't address the fundamental evidence gap.

The July meeting won't be the final word. The PCAC makes recommendations, not binding decisions. The FDA can follow or ignore them. And a second meeting is scheduled before the end of February 2027 to review five more peptides, including GHK-Cu, Dihexa, and Melanotan II.

Category 1 listing is not FDA approval. Even if the PCAC recommends adding these peptides to the 503A bulk drug list, that only means compounding pharmacies can legally prepare them. It does not mean they are FDA-approved drugs with established safety and efficacy profiles. That distinction matters.

The Oria Take

We believe in the potential of peptide science. The GLP-1 agonists — semaglutide, tirzepatide — are proof that peptides can be transformative when backed by rigorous clinical evidence. Those drugs went through years of Phase 1, 2, and 3 trials involving tens of thousands of participants before receiving FDA approval.

The peptides under review at the July PCAC meeting haven't gone through that process. Some have no human data at all. That's not a political statement — it's a factual one. And it's the same standard we'd apply to any therapeutic intervention, whether it's a peptide, a small molecule, or a biologic.

The FDA scientists' briefing documents aren't anti-peptide. They're pro-evidence. And until the evidence catches up with the hype, the most responsible approach is to stick with compounds that have been studied in humans at scale — and to be honest about what we know and don't know for the rest.

The July 23-24 meeting will be livestreamed and open to the public. The public docket (FDA-2025-N-6895) is open for comments until July 22. If you have a stake in this — as a patient, clinician, or researcher — this is the moment to make your voice heard.

Evidence Grade: B — Regulatory/political analysis supported by multiple major news outlets (NPR, WaPo, NBC, Guardian), FDA briefing documents, and peer-reviewed evidence reviews. Clinical evidence for individual peptides ranges from C (limited human data) to D (no human data).

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Peptide therapies discussed here are not FDA-approved for the uses described unless specifically noted. Always consult a qualified healthcare provider before starting any new treatment. Oria BioStack provides evidence-based information to help you have informed conversations with your doctor — we do not sell or prescribe peptides.